Right to Treat Act

Bill Number

S. 1830

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.

Last Updated

2026-04-06T20:30:38Z

AI-Generated Summary

Purpose

The "Right to Treat Act" (S. 1830) aims to limit the federal government's role in regulating medical practices by clarifying that agencies within the Department of Health and Human Services (HHS), such as the Food and Drug Administration (FDA), National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), lack authority to do so. It seeks to protect physicians' ability to prescribe medications for uses not officially approved by the FDA, while carving out exceptions for certain controversial procedures.

Key Provisions

• Prohibition on Regulating Medical Practice: No federal agency, including the FDA, NIH, and CDC, can regulate how medicine is practiced by licensed professionals.
• Allowance for Off-Label Drug Use: Federal laws, rules, regulations, or policies cannot block or limit doctors from prescribing or dispensing FDA-approved drugs (or those authorized under emergency use provisions of the Federal Food, Drug, and Cosmetic Act) for unapproved purposes, often called "off-label" use.
• Exceptions (Rule of Construction): The act does not change existing federal restrictions on practices such as abortion, assisted suicide, euthanasia (mercy killing), coercive family planning, female genital mutilation, or medical interventions for gender transition.

Significant Changes to Existing Law

• This bill introduces a explicit statutory limit on federal agencies' authority over medical practice, which previously relied on interpretations of broader laws like the Federal Food, Drug, and Cosmetic Act. It overrides any conflicting federal rules that might restrict off-label prescribing, potentially invalidating agency guidance or enforcement actions in this area.
• It does not alter state-level regulations on medical practice, preserving states' traditional role in licensing doctors and overseeing healthcare.

Potential Impacts

• On Government Agencies: HHS agencies like the FDA, NIH, and CDC would have reduced oversight of how approved drugs are used in clinical settings, potentially limiting their ability to issue safety warnings or guidelines on off-label applications. This could streamline drug access but might complicate public health responses to emerging issues, such as drug misuse or shortages.
• On Citizens: Patients could gain easier access to treatments via off-label prescriptions, benefiting those with unmet medical needs (e.g., rare conditions). However, it might increase risks if unproven uses lead to adverse effects without federal safeguards.
• On International Relations: Minimal direct impact, though it could influence how U.S. drug approval standards are viewed globally, potentially affecting collaborations on international health initiatives or trade in pharmaceuticals.

Main Stakeholders Affected

• Physicians and Healthcare Providers: Gain greater autonomy in treatment decisions, reducing fear of federal penalties for off-label prescribing.
• Patients and Consumers: Benefit from expanded treatment options but face potential variability in care quality due to less uniform federal standards.
• Pharmaceutical Companies: Could see increased market use of existing drugs without needing new approvals, though liability concerns might arise.
• Federal Health Agencies (FDA, NIH, CDC): Face constrained authority, possibly shifting more responsibility to states or private entities.
• Advocacy Groups: Pro-life organizations, medical freedom advocates, and those opposing certain procedures (e.g., gender-affirming care) may support the exceptions, while public health groups might oppose the limits on agency power.

Notable Legal, Constitutional, or Political Implications

• Legal Implications: The bill could lead to court challenges testing the scope of federal versus state authority over medicine (a domain traditionally left to states under the U.S. Constitution's 10th Amendment). It might also conflict with existing FDA enforcement powers, prompting litigation over whether it unconstitutionally restricts Congress's commerce clause authority to regulate interstate drug markets.
• Constitutional Implications: Reinforces federalism by curbing executive branch overreach, but raises questions about whether it adequately balances public safety with individual rights under the due process clause.
• Political Implications: As an introduced bill in the 119th Congress (referred to the Senate Committee on Health, Education, Labor, and Pensions), it reflects debates on government intervention in healthcare, potentially appealing to those favoring deregulation while drawing criticism for undermining evidence-based public health protections. If enacted, it could set a precedent for limiting agency rulemaking in other sectors.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Johnson, Ron [R-WI]

Recent Actions

• 2026-03-19: Committee on Health, Education, Labor, and Pensions. Hearings held.
• 2025-05-21: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• 2025-05-21: Introduced in Senate

Bill Versions

• Right to Treat Act — issued 2025-05-21 — PDF (2 pages)